Products
AAV9 vector system (AAV9 expression system, AAV9 packaging plasmid system)
AAV protocol Download AAV User Manual Download AAV serotype 9 (AAV capsid 9) system - Introduction
GeneMedi's AAV9 Vector System (AAV serotype 9 helper-free packaging plasmids system) is including AAV9 Rep-Cap plamid (AAV9-RC plasmid, or called AAV-RC9 plasmid), AAV helper plasmid and AAV expression vectors (overexpression or shRNA).
GeneMedi's AAV expression vectors have been inserted with differernt expression cassettes, containing kinds of verified protomters and reporters including GFP, zsgreen, RFP, mcherry and luciferase. The GeneMedi's AAV expression vectors have been proved very suitalble for unique gene overexpression or shRNA-mediated knock-down (also called RNAi (RNA interference ). You can also achieve gene knock-out(KO) or gene editing using our Crispr-cas9-gRNA AAV expression vector.
AAV9 Rep-Cap plamid supplies the AAV2 Rep(replication) proteins and the AAV9 capsid protein.
The tissue tropism of AAV9 vector has been validated in neuron (CNS), lung, liver, heart and muscle, with potential applications in tissue-specific gene therapy.
| Product Name | Organization Type | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| AAV9 vector system Cat.No.:P-PK13 1. AAV9 Rep-Cap Plasmid, 5ug2. AAV Helper Plasmid, 5ug3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug | Academic | 2028 | ||
| AAV9 vector system Cat.No.:P-PK13 1. AAV9 Rep-Cap Plasmid, 5ug2. AAV Helper Plasmid, 5ug3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug | Industry R&D (excluding CRO&CDMO&CXO) | Inquiry | ||
| AAV9 vector system Cat.No.:P-PK13 1. AAV9 Rep-Cap Plasmid, 5ug2. AAV Helper Plasmid, 5ug3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug Expression vector refers only to B01, if you need other expression vector, please click →AAV Expression Vector list | CRO&CDMO& CXO&CMC& Manufacturing company | Inquiry | ||
| If you want to obtain higher quantities of plasmids (mg), please visit GM TransExcellent Plasmid DNA Rapid Preparation Service. | ||||
| Shipping Cost: | 169.00 | |||
| Total: | ||||
AAV9 vector tissue tropism and gene transduction (serotype-specific AAV infection)
The tissue tropism of AAV9 vector has been validated in neuron(CNS), heart, muscle, retina and Pancreas, with potential applications in tissue-specific gene therapy.
.webp)
Virus and titer: AAV9-GFP, AAV9-pTBG-Luciferase (AAV-Luc), 1.4×1012 vg/ml Animal: mouse, C57, 2 months Gene delivery method: tail vein, 100μl Determine assay: 3 weeks post infection, frozen section, immunofluorescence microscopy, in vivo imaging Conclusion: intravenous injection of AAV9-pTBG-Luciferase (AAV-Luc) only infects liver cells and no non-specific infection
Virus and titer: AAV9-GFP, 1×1012 vg/ml Animal: Rat, SD, 2 months (Figure 8A, B, C); mouse, C57, 8 months (Figure 8D) Infection site: heart Gene delivery method: myocardial in situ injection, 10μl/site, 5 sites in total (Figure 8A, B, C);intraorbital intravenous injection (Figure 8D) Determine assay: 3 weeks post infection, frozen section, immunofluorescence microscopy
Virus and titer: AAV9-GFP, 1×1012 vg/ml Animal: Mouse, C57, 2 months Infection site: Brain Gene delivery method: Brain localization injection, 1μl Determine assay: 3 weeks post infection, frozen section, immunofluorescence microscopy
Virus and titer: AAV9-GFAP-GFP, 1×1012 vg/ml Animal: mouse, C57, 2 months Infection site: Hippocampus Gene delivery method: Brain localization injection, 1μl Determine assay: 3 weeks post infection, wholemount, immunofluorescence microscopy
-and-AAV9-GFP.webp)
Virus and titer: AAV9-Luciferase (AAV-Luc), AAV9-GFP, 1×1012 vg/ml Animal: Mouse, C57, 2 months Infection site: Skeletal muscles Gene delivery method: Muscle in situ injection, 10μl/site, 4 sites in total Determine assay: 4 weeks post infection, in vivo imaging, frozen section, immunofluorescence microscopy
Virus and titer: AAV-DJ-GFP, AAV9-GFP, 1×1012 vg/ml Animal: mouse, C57, 2 months Infection site: Kidney Gene delivery method: Multiple sites injection in kidney 10μl/site, 6 sites in total Determine assay: 3 weeks post infection, frozen section, immunofluorescence microscopy
Virus and titer: AAV2 (left) /AAV-DJ (middle) / AAV9 (right), 1×1012 vg/ml Animal: Nude mouse, 2 months Infection site: Subcutaneous transplant of bowel cancer cells Gene delivery method: Tumor injection, 10μl/site, 4 sites in total Determine assay: 3 weeks post infection, frozen section, immunofluorescence microscopy
Virus and titer: AAV9-GFP, 1×1012 vg/ml Animal: mouse, C57, 2 months Infection site: Mammary fat pad Gene delivery method: Breast injection, 10μl/site, 4 sites in total Determine assay: 3 weeks post infection, frozen section, immunofluorescence microscopy
Virus and titer: AAV2 (left) /AAV-DJ (middle) / AAV9 (right), 1×1012 vg/ml Animal: Nude mouse, 2 months Infection site: Subcutaneous transplant of bowel cancer cells Gene delivery method: Tumor injection, 10μl/site, 4 sites in total Determine assay: 3 weeks post infection, frozen section, immunofluorescence microscopy
Virus and titer: AAV1/AAV6/AAV8/AAV-Rh10/AAV-DJ/AAV9-GFP, 1×1012 vg/ml Cells: HEK-293T MOI: MOI=1×104 Determine assay: 36 hours post infection, immunofluorescence microscopy
Other AAV Vector System
Facebook
LinkedIn
Twitter
